Protagonist Therapeutics (PTGX) Long-Term Investments (2016 - 2026)

Protagonist Therapeutics has disclosed Long-Term Investments across 9 years of filings, most recently posting $72.5 million for Q1 2026.

• Long-Term Investments for Q1 2026 came in at $72.5 million, down 41.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $72.5 million (down 41.3% YoY), and the FY2025 annual result was $78.6 million, down 43.93% from the prior year.
• Long-Term Investments came in at $72.5 million for Q1 2026 at Protagonist Therapeutics, down from $78.6 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $140.3 million in Q4 2024 to a low of $2.0 million in Q3 2023.
• The 4-year median for Long-Term Investments is $102.5 million (2025), against an average of $85.3 million.
• Across the five-year window, Long-Term Investments soared 5630.0% in 2024 and plunged 43.93% in 2025, its largest moves.
• Protagonist Therapeutics' Long-Term Investments stood at $2.0 million in 2023, then surged by 6912.6% to $140.3 million in 2024, then tumbled by 43.93% to $78.6 million in 2025, then slipped by 7.81% to $72.5 million in 2026.
• The last three Long-Term Investments figures came in at $72.5 million (Q1 2026), $78.6 million (Q4 2025), and $102.7 million (Q3 2025), per Business Quant data.